Latest news with #IDH
Time of India
11 hours ago
- Health
- Time of India
Hope for AML patients with rare gene mutation
Pune: New and emerging therapies, which cause less collateral damage to normal blood and target specific mutations, are a promising alternative to treat Acute Myeloid Leukemia (AML), several oncologists have said. June is AML awareness month. Specialists have begun using ivosidenib, one such drug, that targets AML with IDH mutation, after Central Drugs Standard Control Organisation approved it in May. You Can Also Check: Pune AQI | Weather in Pune | Bank Holidays in Pune | Public Holidays in Pune India accounts for the highest number of AML cases after the US and China as per statistics from 2021. Dr Sameer Melinkeri, clinical haematologist at Pune's Deenanath Mangeshkar Hospital & Research Centre, said new therapies such as ivosidenib, azacitidine and venetoclax, help precisely target individual mutations in AML. "Ivosidenib is the first targeted therapy developed specifically for AML patients who carry the rare IDH1 gene mutation," said Dr Melinkeri. "It blocks a faulty enzyme—mutant IDH1—that causes the buildup of a harmful substance called 2-hydroxyglutarate in the body. This substance stops blood cells from maturing and spreads cancer cells," the doctor added. He said ivosidenib turns off the cancer-causing switch (mutation) in patients with IDH, a specific gene mutation. By stopping the enzyme, ivosidenib helps blood cells mature normally, reducing cancerous cells and allowing healthy cells to grow. Dr Reshma Puranik, a medical and haemato-oncologist with MOC, Cancer Care and Research Centre said that ivosidenib is a first-in-class, oral, small-molecule inhibitor of the mutant IDH1 enzyme and works well in brain tumors with IDH mutation. In trials, ivosidenib and azacitidine achieved superior outcomes with similar toxicity compared to azacitidine with newly-diagnosed IDH1-mutated AML. "Patients on ivosidenib need to monitor blood counts along with renal and liver function tests, serum electrolytes and QT interval on ECG. Some patients get a minor rash, feel fatigued, have oral mucositis (ulcers) and are at risk of differentiation syndrome," Dr Puranik added. While the new targeted therapies are expensive, more awareness and distributors in the market will bring the cost down, experts say. Dr Shilpa Gupta, consultant haemato-oncologist in a Mumbai-based cancer centre, said, "I have started ivosidenib for a patient and will wait for the results."
Yahoo
22-05-2025
- Business
- Yahoo
Epigenetics Market Research Report 2024-2025 & 2029 - DNMT, IDH, HDAC, and EZH2, are Forecasted to Witness Significant Growth
Growth is driven by increasing epigenetic research influenced by clinical evidence linking epigenetics to various diseases. Epigenetic therapeutics, especially targeting DNMT, IDH, HDAC, and EZH2, are forecasted to see significant growth due to advancements in treatments for cancer. The comprehensive report analyzes market drivers, trends, and opportunities and includes data and insights to aid strategic decision-making. Profiles of leading companies, such as Bristol-Myers Squibb and Thermo Fisher Scientific, are featured. Epigenetics Market Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Epigenetics Market" report has been added to global market for epigenetics research tools and reagents, IVDs and therapeutics is expected to grow from $4.8 billion in 2024 to $8.5 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.8% from 2024 through 2029. This report comprehensively analyzes the global market for epigenetics products, research tools and reagents, epigenetic biomarker-based in vitro diagnostics (IVDs) and epigenetics-targeted therapeutics. It offers both quantitative and qualitative insights to help readers formulate growth strategies, evaluate the market landscape, assess their competitive positions and make informed business decisions regarding epigenetics products and services. The scope of epigenetics-targeted therapeutics includes DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, isocitrate dehydrogenase (IDH) inhibitors and zeste homolog 2 (EZH2) is the study of heritable changes in gene expression or activity that do not involve alterations to the DNA sequence itself. The global market for epigenetics research tools and reagents by study method was estimated at $1.8 billion in 2023. This market should reach $2.2 billion by the end of 2029, growing at a CAGR of 4.1% through the forecast period. The demand for new research tools remains constant as scientists strive to advance understanding and pursue groundbreaking mounting clinical evidence supporting the relevance of epigenetics in various diseases has fueled a surge in epigenetic research, thereby increasing the demand for high-quality reagents and research tools. The trend is expected to continue over the forecast period, yielding market therapeutics target and modulate epigenetic mechanisms to restore a more normal epigenomic configuration. The global market for epigenetic therapeutics market by drug class targeting DNMT, IDH, HDAC and EZH2 was estimated at $938.2 million in 2023. The market is expected to reach $1.9 billion by the end of 2029, growing at a CAGR of 11% over the forecast period. Emerging research demonstrates the potential of epigenetics-based therapeutics as a versatile and targeted treatment modality, offering a viable alternative to conventional chemotherapy. Scientific advances, the growing number of cancer patients and the unmet need in oncology are key growth factors of the epigenetic drugs report includes: Analyses of the trends in global markets for epigenetics technologies, with market revenue data from 2021 to 2023, estimates for 2024, and projected CAGRs through 2029 Estimates of the size and growth forecasts of the global epigenomics market, and a corresponding market share analysis by product type, study method, clinical indication, drug class and region Facts and figures pertaining to the market dynamics, technological advancements, regulatory landscape, and the impact of macroeconomic factors Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses Evaluation of recent patent activity and key granted and published patents in the industry Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook Profiles of leading companies, including Bristol-Myers Squibb Co., Les Laboratoires Servier, Exact Sciences Corp., Thermo Fisher Scientific Inc., and Qiagen Company Profiles Active Motif Inc. Bio-Rad Laboratories Inc. Bio-Techne Bristol-Myers Squibb Co. Daiichi Sankyo Co. Ltd. Exact Sciences Corp. Guardant Health Hologic Inc. Les Laboratoires Servier Merck KGaA Nucleix Promega Corp. Qiagen Revvity Inc. (Perkinelmer) Thermo Fisher Scientific Inc. Key Attributes: Report Attribute Details No. of Pages 115 Forecast Period 2024 - 2029 Estimated Market Value (USD) in 2024 $4.8 Billion Forecasted Market Value (USD) by 2029 $8.5 Billion Compound Annual Growth Rate 11.8% Regions Covered Global Key Topics Covered: Chapter 1 Executive Summary Market Outlook Scope of Report Market Summary Chapter 2 Market Overview Epigenetics Overview DNA Methylation Histone Modification RNA Modifications Epigenetic Modulators Chapter 3 Market Dynamics Market Dynamics Snapshot Market Drivers Rising Prevalence of Cancer and Unmet Need in Oncology Advances in Analytical Technologies and Tools Increasing Investment in Biomedical Research Trend Towards Precision Medicine Growing Interest in Liquid Biopsy Market Restraints From Bench to Bedside: The Translation Gap in Epigenetics Epigenetic Therapeutics: Limited Clinical Success Against Solid Tumors Stringent Regulatory Landscape Market Trends Combining Epigenetic Modifiers with Other Therapeutic Class Multi-omics Integration Long-Read Sequencing in Epigenetic Research Epigenetic Biomarkers-based Blood Test for Cancer Screening Chapter 4 Emerging Technologies and Developments Emerging Technologies Epigenome Editing Epitranscriptomics Bromodomain and Extra-Terminal Domain Inhibitors Menin Inhibitors Application Beyond Oncology Pipeline Analysis Overview Novel Epigenetic Therapeutics in Development in Phase 2 and Above Chapter 5 Market Segmentation Analysis Segmentation Breakdown Epigenetics Research Tools and Reagents Market, by Study Method Market Overview Market Size and Forecast DNA Methylation Histone Modification RNA Modification In Vitro Diagnostics (IVDs) Market, by Clinical Indication Market Overview Market Size and Forecast Epigenetic Therapeutics Market, by Drug Class Market Overview Market Size and Forecast Geographic Breakdown Epigenetics Research Tools and Reagents Market, by Region Market Size and Forecast North America Europe Asia-Pacific Rest of the World Chapter 6 Competitive Intelligence Research Tools and Reagents In Vitro Diagnostics Therapeutics Chapter 7 Sustainability in the Epigenetics Market: An ESG Perspective Introduction to ESG Key ESG Issues in Epigenetics Pharmaceuticals and Diagnostics Market Sustainability Practices in Pharmaceuticals Manufacturing Sustainable Packaging Key ESG Issues in Epigenetics Research Tools Market ESG Risk Ratings Score -- Understanding the Data Concluding Remarks Chapter 8 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Epigenetics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
TECHx
30-01-2025
- Business
- TECHx
IDH Adopts Salesforce to Transform Diagnostics Across MEA - TECHx Media IDH Adopts Salesforce to Transform Diagnostics Across MEA
IDH Adopts Salesforce to Transform Diagnostics Across MEA Integrated Diagnostics Holdings (IDH), a leading pan-regional provider of diagnostic services based in Egypt, is revolutionizing its operations by deploying Salesforce Customer 360. This strategic move aims to digitally transform IDH's extensive network of over 600 labs and diagnostic centers across the Middle East and Africa. The adoption of Salesforce's integrated CRM platform will enhance IDH's operational efficiency, provide full visibility into its processes, and position the company to leverage cutting-edge technologies, including artificial intelligence (AI). IDH's facilities include its state-of-the-art 'Mega Lab' in Egypt, an automated, CAP-accredited laboratory offering a comprehensive range of diagnostic tests. Alongside its hundreds of diagnostic and radiology centers, IDH conducts approximately 30 million diagnostic tests annually, serving 10 million patients across Egypt, Jordan, Nigeria, Saudi Arabia, and Sudan. With the demand for diagnostic services on the rise, IDH has prioritized digital transformation to support its ambitious expansion plans. By implementing Salesforce Customer 360, IDH will gain a unified view of its operations, including headcounts, patient visits, margins, and financial performance. This integrated platform will streamline workflows across its labs and radiology centers, improving collaboration with partners such as doctors and hospitals that refer patients for diagnostics. Dr. Hend El Sheribini, Group CEO of IDH, emphasized the significance of this transformation, stating, 'IDH already plays a pivotal role in healthcare across our markets, delivering advanced diagnostics and supporting millions of people annually. By partnering with Salesforce, we are enhancing our agility and efficiency, enabling us to better serve our partners and customers.' Sherif El Zeiny, Board Member and Vice President of IDH, highlighted the platform's role in driving growth and innovation. 'Salesforce Customer 360 will help us strengthen our bottom line amid increasing competition and support our expansion into new markets. It also positions us to adopt transformative technologies like AI as we continue our journey of innovation.' The implementation of Salesforce Customer 360 is being led by Cloudzlab, a Salesforce Platinum Cloud Alliance partner headquartered in Cairo and Dubai. The platform will empower IDH's field representatives with real-time data, improving planning and strengthening partnerships. Additionally, it will provide management and finance teams with enhanced visibility into lead-to-cash cycles, forecasting, and opportunity management. Frank Defesche, Senior Vice President and General Manager of Life Sciences at Salesforce, praised IDH's transformation efforts. 'IDH exemplifies how organizations can unify and simplify operations through a comprehensive digital platform. This transformation not only boosts internal efficiency but also strengthens customer and partner relationships, showcasing the power of a customer-first approach.' IDH's adoption of Salesforce Customer 360 marks a significant step in its digital transformation journey, enabling the company to deliver superior diagnostic services while embracing innovative technologies like AI. This collaboration underscores IDH's commitment to advancing healthcare across the Middle East and Africa.
Zawya
30-01-2025
- Business
- Zawya
Integrated Diagnostics Holdings drives agility and efficiency across its operations with Salesforce
Dubai, UAE - Integrated Diagnostics Holdings (IDH), an Egypt-based pan-regional provider of diagnostic services, is deploying Salesforce Customer 360 to digitally transform its operations, including its more than 600 labs and diagnostic centres across the Middle East and Africa. The move will enable IDH to raise its efficiency and agility, gain full visibility of its operations, and position it to embrace transformative technologies including artificial intelligence (AI). IDH's facilities include its 'Mega Lab', an automated and CAP-accredited lab in Egypt, which provides a full suite of diagnostic tests, in addition to its hundreds of diagnostic and radiology centres. The company performs approximately 30 million diagnostic tests serving 10 million patients each year in Egypt, Jordan, Nigeria, Saudi Arabia and Sudan. With demand for diagnostic services soaring, and to support its ambitious expansion plans, IDH decided to digitally transform its operations by deploying Salesforce Customer 360, giving it full visibility of its operations including headcounts, visits across its network, margin and bottom line through a single, integrated CRM that connects all its departments and data. This will help IDH improve its workflow for thousands of tests across its labs and radiology centres, improving its interactions with its partners, including doctors at thousands of clinics and hospitals who refer patient diagnostics to its labs. 'IDH already plays a pivotal role in healthcare in the markets in which it operates, delivering state-of-the-art diagnostics and supporting the healthcare of millions of people every year,' said Dr. Hend El Sheribini, IDH Group CEO. 'By transforming our operations with Salesforce, we will raise our agility and efficiency, improving our ability to serve our partners and customers.' Sherif El Zeiny, Board Member and Vice President of IDH, added, 'With Salesforce Customer 360, we will be able to continue to raise our bottom line at a crucial time, as competition increases, and we continue to drive ahead with an ambitious expansion plan including opening new diagnostic centres in our existing markets and entering new markets in the region. It will also position us to enhance our use of innovative technologies including AI, as we continue our journey of continual transformation.' The implementation of the platform will be conducted by Cloudzlab, a collaborative, innovative consultancy company and a Salesforce Platinum Cloud Alliance partner, headquartered in Cairo and Dubai and serving the EMEA region. The Salesforce platform will also help ensure that IDH's field reps on the ground have accurate live data on their caseloads with doctors, helping to improve planning and elevate partnerships. The platform will also improve visibility for management and finance teams, giving them greater clarity on lead to cash cycles, forecasting and opportunity management. Frank Defesche, Senior Vice President and General Manager, life sciences at Salesforce, said: 'IDH stands out as a great example of an organisation that was able to successfully unify and simplify its operations around a single, comprehensive digital platform. With this transformation, IDH is not only improving its internal efficiency, but also creating stronger connections with partners and customers, reinforcing the type of agility and customer-first approach that innovations like Agentforce would enable across industries. We are delighted with the collaboration and look forward to our continued support of IDH on its digital transformation and AI journey.' -Ends- About Salesforce Salesforce helps organizations of any size reimagine their business for the world of AI. With Agentforce, Salesforce's trusted platform, organizations can bring humans together with agents to drive customer success—powered by AI, data, and action. Visit for more information. For more information about Salesforce (NYSE: CRM), visit:
